<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6e384a23-a8c4-455a-b84b-847393d491e6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DEFEROXAMINE MESYLATE FOR INJECTION safely and effectively. See full prescribing information for DEFEROXAMINE MESYLATE FOR INJECTION.<br/>
      <br/>DEFEROXAMINE MESYLATE for Injection, for intramuscular, intravenous, or subcutaneous use<br/>Initial U.S. Approval: 1968 </title>
   <effectiveTime value="20250320"/>
   <setId root="d91e16df-8daa-4cd2-86a2-273eaa2446e0"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="840771732" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-597" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-599" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-597" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-599" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023648251" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-597" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-599" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-597" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-599" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="508e31a1-6c4a-46ad-a368-f2af91d0c6f5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-599" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deferoxamine<suffix/>
                        </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DEFEROXAMINE MESYLATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="95"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V9TKO7EO6K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFEROXAMINE MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J06Y7MXW4D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFEROXAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="21.1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-599-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20091215"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078718" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20091215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-597" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deferoxamine<suffix/>
                        </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DEFEROXAMINE MESYLATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="95"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V9TKO7EO6K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFEROXAMINE MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J06Y7MXW4D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFEROXAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5.3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-597-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20091215"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078718" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20091215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="e4cd7027-86a9-4d6a-9ca6-6d9bf4699ee0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is an iron-chelating agent indicated: </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>As an adjunct to standard measures for the treatment of acute iron intoxication. (<linkHtml href="#s2">1.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>For the treatment of transfusional iron overload in patients with chronic anemia. (<linkHtml href="#s3">1.2</linkHtml>) </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2">
                     <id root="8781834a-5d2a-48b0-a27a-fc54790e0955"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Acute Iron Intoxication </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s3">
                     <id root="c572a6e2-9d50-498c-a933-ea04abf39ad0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Chronic Iron Overload </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="b82832dd-c198-4156-b506-f0a8b81d7984"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Limitations of Use </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="0750cecb-f1ce-4d9a-b513-da23ab3eae31"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient's iron overload. The minimum daily dose of Deferoxamine Mesylate for Injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults. </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Iron Intoxication:</content> (<linkHtml href="#s6">2.1</linkHtml>) </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Intramuscular Administration: Use for patients not in shock. Initial dose is 1,000 mg. Depending upon the clinical response, subsequent doses of 500 mg may be administered every 4 hours to 12 hours. Maximum dose is 6,000 mg in 24 hours. </item>
                           <item>
                              <caption>•</caption>Intravenous Administration: Only for patients in a state of cardiovascular collapse. Initial dose is 1,000 mg at a rate not to exceed 15 mg/kg/hr. Depending upon the clinical response, subsequent doses of 500 mg may be administered every 4 hours to 12 hours at a rate of up to 125 mg/hr. Maximum dose is 6,000 mg in 24 hours </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Chronic Iron Overload</content>: (<linkHtml href="#s9">2.2</linkHtml>) </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Subcutaneous Infusion: Average daily dose is between 20 and 60 mg/kg. In patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. Patients with serum ferritin level between 2,000 and 3,000 ng/mL require about 35 mg/kg/day. Patients with higher serum ferritin may require up to 55 mg/kg/day. </item>
                           <item>
                              <caption>•</caption>Intravenous Administration: 20 mg/kg/day to 40 mg/kg/day for pediatric patients and 40 mg/kg/day to 50 mg/kg/day over 8 hours to 12 hours in adults for 5 days to 7 days per week. In pediatric patients and adults, maximum dose should not exceed 40 mg/kg/day and 60 mg/kg/day, respectively. </item>
                           <item>
                              <caption>•</caption>Intramuscular Administration: 500 mg to maximum daily dose of 1,000 mg. </item>
                        </list>
                        <paragraph>See Full Prescribing Information for instructions on preparation of Deferoxamine Mesylate for Injection for administration. (<linkHtml href="#s13">2.3</linkHtml>) </paragraph>
                        <paragraph>Vitamin C (up to 200 mg) increases availability of iron for chelation and may be given as an adjuvant to iron chelation therapy. (<linkHtml href="#s14">2.4</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6">
                     <id root="79ccfdb9-7a13-4973-8ced-5448c8ac96bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage for Treatment of Acute Iron Intoxication for Adults and Pediatric Patients </title>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="s7">
                           <id root="caa19e32-a8c6-42b0-b982-1e4ebb225afd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Intramuscular (IM) Administration</content>
                              </paragraph>
                              <paragraph>Use for all patients not in shock. </paragraph>
                              <paragraph>The initial recommended dose of Deferoxamine Mesylate for Injection is 1,000 mg intramuscularly (IM) once. If needed based on the clinical response, administer subsequent doses of 500 mg every 4 hours to 12 hours. The maximum recommended daily dose is 6,000 mg in 24 hours. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s8">
                           <id root="4c7fd903-4864-467b-8b38-66ca6cb65c06"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Intravenous (IV) Administration</content>
                              </paragraph>
                              <paragraph>Administer Deferoxamine Mesylate for Injection intravenously (IV) to patients in a state of cardiovascular collapse and then only by slow infusion. As soon as the clinical condition of the patient permits, intravenous administration should be discontinued, and the drug should be administered intramuscularly. </paragraph>
                              <paragraph>The initial recommended IV dose of Deferoxamine Mesylate for Injection is 1,000 mg administered at an infusion rate of up to 15 mg/kg/hr. If needed based on the clinical response administer additional doses of 500 mg over 4 hours to 12 hours at a slower infusion rate of up to 125 mg/hr. The maximum recommended daily dose is 6,000 mg in 24 hours. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="9fb5ded9-e691-4bbf-b878-420499479516"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage for Treatment of Chronic Iron Overload for Adults and Pediatric Patients </title>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="s10">
                           <id root="8487c7d0-8021-455a-a7c2-bd516573fe09"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Subcutaneous Infusion Administration</content>
                              </paragraph>
                              <paragraph>The average daily dose of Deferoxamine Mesylate for Injection is usually between 20 and 60 mg/kg. In general patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. Patients with serum ferritin level between 2,000 and 3,000 ng/mL require about 35 mg/kg/day. Patients with higher serum ferritin may require up to 55 mg/kg/day. It is not advisable to regularly exceed an average daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth. If ferritin levels fall below 1,000 ng/mL, the risk of Deferoxamine Mesylate for Injection toxicity increases; it is important to monitor these patients particularly carefully and perhaps to consider lowering the total weekly dose. The doses specified here are the average daily doses. Since most patients use Deferoxamine Mesylate for Injection less than 7 days a week, the actual dose per infusion usually differs from the average daily dose; e.g. if an average daily dose of 40 mg/kg/day is required and the patient wears the pump 5 nights a week, each infusion should contain 56 mg/kg. </paragraph>
                              <paragraph>Slow subcutaneous infusion using a portable, light-weight infusion pump over a period of 8 to 12 hours is regarded as effective and especially convenient for ambulatory patients, but may also be given over a 24-hour period. Deferoxamine Mesylate for Injection should normally be used with the pump 5 to 7 times a week. Deferoxamine Mesylate for Injection is not formulated to support subcutaneous bolus injection. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s11">
                           <id root="9c3a79e8-9862-4ae1-b914-670830c55558"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Intravenous Administration</content>
                              </paragraph>
                              <paragraph>Deferoxamine Mesylate for Injection can be administered intravenously if needed in patients with intravenous access. </paragraph>
                              <paragraph>The recommended dose of Deferoxamine Mesylate for Injection in adults is 40 mg/kg/day to 50 mg/kg/day over 8 hours to 12 hours at a rate of up to 15 mg/kg/hour for 5 days to 7 days per week. Maximum dose is 60 mg/kg/day. </paragraph>
                              <paragraph>The recommended dose of Deferoxamine Mesylate for Injection in pediatric patients is 20 mg/kg/day to 40 mg/kg/day over 8 hours to 12 hours for 5 days to 7 days per week. The maximum recommended daily dose is 40 mg/kg/day until growth (body weight and linear growth) has ceased. </paragraph>
                              <paragraph>In case of missed doses, Deferoxamine Mesylate for Injection may be administered prior to or following same day blood transfusion (for example, 1 gram over 4 hours on the day of transfusion); however, the contribution of this mode of administration to iron balance is limited. Deferoxamine Mesylate for Injection should not be administered concurrently with the blood transfusion as this can lead to errors in interpreting side effects such as rash, anaphylaxis and hypotension. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s12">
                           <id root="f0eb252f-99b1-40e6-a9e7-bf033d39c3bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Intramuscular Administration</content>
                              </paragraph>
                              <paragraph>If given intramuscularly, the recommended dose of Deferoxamine Mesylate for Injection is 500 mg to 1,000 mg per day. The maximum recommended daily dose is 1,000 mg per day. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="09f25735-9f96-4057-aade-3842de638ea1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation </title>
                     <text>
                        <paragraph>Reconstitute Deferoxamine Mesylate for Injection prior to administration. Deferoxamine Mesylate for Injection should be further diluted for intravenous infusion. Use appropriate aseptic technique. </paragraph>
                        <paragraph>Reconstitute each vial of Deferoxamine Mesylate for Injection with Sterile Water for Injection, USP per <linkHtml href="#_Reft1">Table 1</linkHtml>. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if visibly opaque particles, discoloration or foreign particles are observed. The reconstituted Deferoxamine Mesylate for Injection solution is an isotonic, clear and colorless to slightly-yellowish solution. Discard unused portion. </paragraph>
                        <table ID="_Reft1" width="100%">
                           <caption>Table 1. Preparation of Deferoxamine Mesylate for Injection Prior to Administration </caption>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4" styleCode="Botrule" valign="top">*Intravenous route of administration requires further dilution with 150 mL of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP or Lactated Ringers Injection, USP </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4" styleCode="Botrule" valign="top">**Final concentration for intravenous administration is between 3 mg/mL to 3.5 mg/mL </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Vial Size </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>Route of Administration </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>Amount of Sterile Water for Injection, USP for Reconstitution </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>Concentration After Reconstitution </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Intramuscular </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>2 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>213 mg/mL </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Intravenous* </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>5 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>95 mg/mL** </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Subcutaneous </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>5 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>95 mg/mL </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2 grams </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Intramuscular </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>8 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>213 mg/mL </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2 grams </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Intravenous* </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>95 mg/mL </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>2 grams </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Subcutaneous </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>95 mg/mL </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>If not used immediately, store at room temperature between 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F), for a maximum period of 24 hours. Do not refrigerate reconstituted solution. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="e3f3b400-c79e-4955-ae64-a323da907f13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Management of Vitamin C Deficiency </title>
                     <text>
                        <paragraph>Patients with iron overload usually become vitamin C deficient, probably because iron oxidizes the vitamin. As an adjuvant to iron chelation therapy, vitamin C in doses up to 200 mg for adults may be given in divided doses, starting after an initial month of regular treatment with Deferoxamine Mesylate for Injection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.7</linkHtml>)]</content>. Vitamin C increases availability of iron for chelation. In general, 50 mg daily suffices for pediatric patients under 10 years old and 100 mg daily for older pediatric patients. Larger doses of vitamin C fail to produce any additional increase in excretion of iron complex. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="6075f0c6-9a6a-4c21-92fc-889d476343a4"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>For injection: 500 mg of deferoxamine mesylate (corresponding to 426.82 mg of deferoxamine as free base) is a white to off-white lyophilized powder in a single-dose vial for reconstitution. </paragraph>
                  <paragraph>For injection: 2 grams of deferoxamine mesylate (corresponding to 1.707 g of deferoxamine as free base) is a white to off-white lyophilized powder in a single-dose vial for reconstitution. </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 500 mg and 2 g of deferoxamine mesylate is a white to off-white lyophilized powder in single-dose vial for reconstitution (<linkHtml href="#s15">3</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="964a6b65-4fec-4cf2-87d2-4e376c06d413"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Deferoxamine Mesylate for Injection is contraindicated in patients with: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients <content styleCode="italics">[see Description (<linkHtml href="#s50">11</linkHtml>)]</content>. Reactions have included anaphylaxis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>. </item>
                     <item>
                        <caption>•</caption>Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.3</linkHtml>)]</content>. </item>
                  </list>
               </text>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Known hypersensitivity to the active substance. (<linkHtml href="#s16">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Patients with severe renal disease or anuria. (<linkHtml href="#s16">4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="d316411f-a368-417d-bd52-00996cdef0a5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity Reactions: More common with rapid intravenous infusion. Administer intramuscularly or by slow subcutaneous or intravenous infusion. (<linkHtml href="#s18">5.1</linkHtml>) Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. (<linkHtml href="#s19">5.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Renal Toxicity: Cases of acute renal failure, renal tubular disorders and increase in serum creatinine have occurred. Monitor patients for changes in renal function. (<linkHtml href="#s20">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Respiratory Toxicity: Acute respiratory distress syndrome has occurred. Risk increased with high intravenous doses. Recommended daily dose should not be exceeded. (<linkHtml href="#s21">5.4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Growth Suppression: Has occurred in pediatric patients treated with high doses and concomitant low ferritin levels. Dose reduction may partially resume growth velocity to pre-treatment rates. (<linkHtml href="#s22">5.5</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Serious Infections: Cases of mucormycosis and Yersinia infections, some fatal, have occurred. Discontinue Deferoxamine Mesylate for Injection and initiate appropriate treatment immediately. (<linkHtml href="#s23">5.6</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Cardiac Dysfunction with Concomitant Use of Vitamin C: Avoid coadministration in patients with cardiac failure. Delay Vitamin C for one month after start of Deferoxamine Mesylate for Injection. Avoid exceeding 200 mg daily in adults. Monitor cardiac function with combined treatment. (<linkHtml href="#s26">5.7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload: Risks include neurological dysfunction (including seizures), dialysis dementia, and aggravation of hyperparathyroidism. (<linkHtml href="#s27">5.8</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Effects on Ability to Drive and Use Machines: May cause dizziness. (<linkHtml href="#s28">5.9</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use effective contraception (<linkHtml href="#s29">5.10</linkHtml>, <linkHtml href="#s36">8.1</linkHtml>, <linkHtml href="#s41">8.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s18">
                     <id root="fcbdcb3f-b4b6-49b3-83eb-a68897178e57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including anaphylaxis, have occurred in Deferoxamine Mesylate for Injection-treated patients. Reactions have included flushing of the skin, urticaria, hypotension, and shock. These reactions typically occur when Deferoxamine Mesylate for Injection was administered by rapid intravenous injection. Therefore, administer Deferoxamine Mesylate for Injection intramuscularly or by slow subcutaneous or intravenous infusion. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="f989bea0-5f58-48fa-8291-3e0abdc112af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Auditory and Ocular Toxicity </title>
                     <text>
                        <paragraph>Ocular and auditory toxicities have been reported in Deferoxamine Mesylate for Injection-treated patients. The ocular toxicities observed have included blurring of vision; cataracts after prolonged administration in chronic iron overload; decreased visual acuity, including visual loss, visual defects, scotoma; impaired peripheral, color, and night vision; optic neuritis, cataracts, corneal opacities, and retinal pigmentary abnormalities. The auditory toxicities reported have been tinnitus and hearing loss, including high frequency sensorineural hearing loss. Risk factors for both ocular and auditory disturbances include prolonged treatment duration, higher doses, or low ferritin levels. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s30">6</linkHtml>)]</content>. </paragraph>
                        <paragraph>Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommended periodically in patients treated for prolonged periods of time. Toxicity is more likely to be reversed if symptoms or test abnormalities are detected early. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="a2365aab-49dd-4497-a68a-e874bae78ec1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Renal Toxicity </title>
                     <text>
                        <paragraph>Renal toxicity, including increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular disorders has occurred in Deferoxamine Mesylate for Injection-treated patients. Deferoxamine Mesylate for Injection is contraindicated in patients with severe renal disease <content styleCode="italics">[see Contraindications (<linkHtml href="#s16">4</linkHtml>)]</content>. Monitor serum creatinine to assess for changes in renal function. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="880550b1-c7e5-4425-92f9-067bb7be1042"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Respiratory Toxicity </title>
                     <text>
                        <paragraph>Acute respiratory distress syndrome has occurred in Deferoxamine Mesylate for Injection-treated patients following treatment with excessively high intravenous doses of Deferoxamine Mesylate for Injection in patients with acute iron intoxication or thalassemia. The recommended daily doses should therefore not be exceeded. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="87af689c-83fc-4ee4-8162-a7c1c17fe5cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Growth Suppression </title>
                     <text>
                        <paragraph>High doses of Deferoxamine Mesylate for Injection and concomitant low ferritin levels have also been associated with growth suppression in pediatric patients. After reduction of Deferoxamine Mesylate for Injection dose, growth velocity may partially resume to pre-treatment rates. Monitor growth (weight and height) in pediatric patients treated with Deferoxamine Mesylate for Injection every 3 months. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="04393d1b-e5ed-4b36-8952-7f419e42d460"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Serious Infections </title>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="s24">
                           <id root="f55286fb-6ad0-4848-9698-4abf5f8966a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Yersinia Infections</content>
                              </paragraph>
                              <paragraph>Deferoxamine Mesylate for Injection may increase the risk of <content styleCode="italics">Yersinia enterocolitica</content> and <content styleCode="italics">Yersinia pseudotuberculosis</content> infections. Avoid starting Deferoxamine Mesylate for Injection treatment in patients with active Yersinia infections. Should Yersinia infection develop, interrupt Deferoxamine Mesylate for Injection treatment until the infection is resolved. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s25">
                           <id root="6d7f38e8-35ec-4888-b28b-bc4798371029"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Mucormycosis</content>
                              </paragraph>
                              <paragraph>Cases of mucormycosis, some with a fatal outcome, have occurred in Deferoxamine Mesylate for Injection-treated patients. Signs or symptoms are specific to the site of infection. If mucormycosis is suspected, discontinue Deferoxamine Mesylate for Injection, conduct mycological testing, and treat immediately. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="064dbcac-7ece-4424-ac23-c8bea50cf3fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Cardiac Dysfunction with Concomitant Use of Vitamin C </title>
                     <text>
                        <paragraph>Cardiac dysfunction has occurred in Deferoxamine Mesylate for Injection-treated patients with severe chronic iron overload following concomitant treatment with high doses of vitamin C (more than 500 mg daily in adults). The cardiac dysfunction was reversible when vitamin C was discontinued. The following precautions should be taken when vitamin C and Deferoxamine Mesylate for Injection are to be used concomitantly: </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Vitamin C supplements should not be given to patients with cardiac failure. </item>
                           <item>
                              <caption>•</caption>Start supplemental vitamin C only after an initial month of regular treatment with Deferoxamine Mesylate for Injection. </item>
                           <item>
                              <caption>•</caption>Give vitamin C only if the patient is receiving Deferoxamine Mesylate for Injection regularly, ideally soon after setting up the infusion pump. </item>
                           <item>
                              <caption>•</caption>Do not exceed a daily vitamin C dose of 200 mg in adults, given in divided doses. In general, 50 mg daily suffices for pediatric patients under 10 years old and 100 mg for older pediatric patients. </item>
                           <item>
                              <caption>•</caption>Clinical monitoring of cardiac function is advisable during such combined therapy. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s27">
                     <id root="14f9a240-db8b-4496-824a-f6862acdae42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection may cause neurological dysfunction (including seizures) in patients with aluminum-related encephalopathy and receiving dialysis, possibly due to an acute increase in circulating aluminum <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s30">6</linkHtml>)]</content>. </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection may precipitate the onset of dialysis dementia. </paragraph>
                        <paragraph>Treatment with Deferoxamine Mesylate for Injection in the presence of aluminum overload may result in decreased serum calcium and aggravation of hyperparathyroidism. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s28">
                     <id root="5f3956b9-ae0c-4b30-925b-ad3f921b239b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Effects on Ability to Drive and Use Machines </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection may cause dizziness, which may impair the ability to drive a car or operate machinery. Patients should not drive or operate machinery until they know how Deferoxamine Mesylate for Injection will affect their ability to engage in these activities. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s29">
                     <id root="057415b1-56eb-4d16-bf12-21d7874e2c1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on findings in animals, Deferoxamine Mesylate for Injection can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of deferoxamine to pregnant mice and rabbits during the period of organogenesis caused adverse developmental outcomes including decreased fetal body weights and malformations at maternal doses less than those in patients at maximum recommended human dose (MRHD). Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Deferoxamine Mesylate for Injection and for one month after the last dose <content styleCode="italics">[see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (<linkHtml href="#s55">13.1</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="6929a93b-9c1f-4043-9d44-645f15510443"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Auditory and Ocular Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Renal Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Respiratory Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.4</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Growth Suppression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Serious Infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.6</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cardiac Dysfunction with Concomitant Use of Vitamin C <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.7</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s27">5.8</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Effects on Ability to Drive and Use Machines <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s28">5.9</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are injection reactions (local and systemic), hypersensitivity reactions, infections with Yersinia and Mucormycosis, cardiovascular, gastrointestinal, hematologic, hepatic, musculoskeletal, urogenital, nervous, respiratory, ocular and hearing. (<linkHtml href="#s30">6</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi, USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s31">
                     <id root="13c14422-4460-4f09-bd6b-0ec34b128db0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>The following adverse reactions associated with the use of deferoxamine mesylate for injection were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="italics">At the Injection Site:</content> Localized irritation, pain, burning, swelling, induration, infiltration, pruritus, erythema, wheal formation, eschar, crust, vesicles, local edema. Injection site reactions may be associated with systemic allergic reactions <content styleCode="italics">([see Body as a Whole, below)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity Reactions and Systemic Allergic Reactions:</content> Generalized rash, urticaria, anaphylactic reaction with or without shock, angioedema </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole:</content> Local injection site reactions may be accompanied by systemic reactions like arthralgia, fever, headache, myalgia, nausea, vomiting, abdominal pain, or asthma </paragraph>
                        <paragraph>Infections: Yersinia, mucormycosis </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> Tachycardia, hypotension, shock </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive:</content> Abdominal discomfort, diarrhea, nausea, vomiting  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic:</content> Blood dyscrasia (thrombocytopenia, leukopenia)  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic:</content> Increased transaminases, hepatic dysfunction </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal:</content> Muscle spasms. Growth retardation and bone changes (e.g., metaphyseal dysplasia) </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System:</content> Neurological disturbances, including dizziness, peripheral sensory, motor, or mixed neuropathy, paresthesias, seizures; exacerbation or precipitation of aluminum-related dialysis encephalopathy </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses:</content> High-frequency sensorineural hearing loss, tinnitus visual disturbances including acuity, blurred vision, loss of vision, dyschromatopsia, night blindness, visual field defects, scotoma, retinopathy (pigmentary degeneration), optic neuritis, and cataracts </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory:</content> Acute respiratory distress syndrome (with dyspnea, cyanosis, and/or interstitial infiltrates) </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin:</content> Generalized rash </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital:</content> Dysuria, acute renal failure, increased serum creatinine and renal tubular disorders </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="e04e153c-1330-47bb-8110-df9738e41f7b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Concurrent treatment with prochlorperazine may lead to temporary impairment of consciousness. (<linkHtml href="#s33">7.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Imaging results may be distorted due to rapid urinary excretion of Deferoxamine Mesylate for Injection bound gallium-67. Discontinue Deferoxamine Mesylate for Injection 48 hours prior to scintigraphy. (<linkHtml href="#s34">7.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s33">
                     <id root="f6066cf9-55ca-4be6-89f1-488199280d74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Prochlorperazine </title>
                     <text>
                        <paragraph>Concurrent treatment with Deferoxamine Mesylate for Injection and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="c0d2f879-3823-4c01-abb8-4ffb8fb7a25a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Gallium-67 </title>
                     <text>
                        <paragraph>Imaging results may be distorted because of the rapid urinary excretion of Deferoxamine Mesylate for Injection-bound gallium-67. Discontinue Deferoxamine Mesylate for Injection 48 hours prior to scintigraphy. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="2031e1e5-a4e9-4371-a77c-83e707d94345"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Lactation: Advise not to breastfeed (<linkHtml href="#s40">8.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Geriatric Use: Increased risk of ocular disorders (<linkHtml href="#s45">8.5</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s36">
                     <id root="b93a9f8d-8358-44ec-ad97-9437b7510d60"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="s37">
                           <id root="e1803561-9b33-4a23-ba47-3bd752fd342a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on Deferoxamine Mesylate for Injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. </paragraph>
                              <paragraph>In animal reproduction studies subcutaneous administration of deferoxamine to pregnant animals (mice or rabbits) during organogenesis at doses approximately ≥0.2- (mice) and ≥0.7 (rabbits) times the maximum recommended human dose resulted in maternal toxicity and adverse developmental outcomes <content styleCode="italics">(see <linkHtml href="#ID_4d79fa1b-d98a-4764-8125-3f518ddef891">Data</linkHtml>)</content>. Advise pregnant women of the potential risk to a fetus. Consider the benefits and risks of Deferoxamine Mesylate for Injection for the mother and possible risks to the fetus when prescribing Deferoxamine Mesylate for Injection to a pregnant woman. </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_4d79fa1b-d98a-4764-8125-3f518ddef891">
                           <id root="5d82315d-794d-4af3-a3c5-2934d54219ab"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In an embryo-fetal developmental study in mice, pregnant animals administered subcutaneous doses of deferoxamine at 180, and 540 mg/kg/day from gestation day 7 to gestation day 12 resulted in a dose dependent delay and irregularities of fetal skeletal maturation at doses ≥0.2 times the MRHD. At the highest dose of 540 mg/kg, in 1/23 fetuses had a unilateral lesion to the eye lens (approximately 0.5 times the MRHD). </paragraph>
                              <paragraph>In the embryo-fetal developmental studies in rabbits, pregnant animals administered subcutaneous doses of deferoxamine either 200 mg/kg or 200, 300, and 540 mg/kg from gestation day 6 to gestation day 14 resulted in maternal toxicity and embryo-fetal developmental effects at 0.7 times the MRHD). Maternal toxicity included reduced fetal body weights and embryo-fetal effects included malformations of spina bifida, and increased incidence of abnormally ossified ribs and vertebrae. </paragraph>
                              <paragraph>No maternal toxicity or embryo-fetal effects were observed in rats at deferoxamine doses tested (up to 0.9 times the MRHD). </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s40">
                     <id root="8b75dc51-0f26-46d8-967f-5b5d6e908b14"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>There are no data on the presence of deferoxamine or its metabolite in either human or animal milk, the effects on the breastfed child, or the effects on milk production. It is not known whether deferoxamine is excreted in human milk. Because of the potential for serious adverse reactions in the breastfed child, advise patients not to breastfeed during treatment with Deferoxamine Mesylate for Injection, and for one week after the last dose. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="082d866e-e2f0-41c9-91d4-26bdb0c15087"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>Based on animal data, Deferoxamine Mesylate for Injection can cause malformations at doses less than the human dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s36">8.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="s42">
                           <id root="2b8a938a-9b10-4635-a970-15462d9fa1a4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                           <component>
                              <section ID="s43">
                                 <id root="13241037-4dde-4b4b-842a-4ab57343869b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Deferoxamine Mesylate for Injection can cause embryo-fetal harm when administered to pregnant women <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s36">8.1</linkHtml>)].</content> Advise female patients of reproductive potential to use effective contraception during treatment with Deferoxamine Mesylate for Injection and for one month after the last dose. </paragraph>
                                 </text>
                                 <effectiveTime value="20250320"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s44">
                     <id root="bcd4a063-7b53-4e7f-997c-afd52f33c2b0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients 3 years of age and older have been established for the treatment of acute iron intoxication and for the treatment of transfusional iron overload in patients with chronic anemia. Safety and effectiveness in pediatric patients under the age of 3 years have not been established. </paragraph>
                        <paragraph>Iron mobilization with Deferoxamine Mesylate for Injection is relatively poor in patients under the age of 3 years with relatively little iron overload. Deferoxamine Mesylate for Injection is not recommended for use. The drug should ordinarily not be given to these patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. </paragraph>
                        <paragraph>High doses of Deferoxamine Mesylate for Injection and concomitant low ferritin levels have been associated with growth suppression in pediatric patients. Monitor weight and height in pediatric patients receiving Deferoxamine Mesylate for Injection every 3 months <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.5</linkHtml>), Adverse Reactions (<linkHtml href="#s31">6.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s45">
                     <id root="94257637-805b-4b06-98e4-9c7541ae6e50"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Clinical Studies of Deferoxamine Mesylate for Injection did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from the younger subjects. Postmarketing reports suggest a possible trend for an increased risk of eye disorders in the geriatric population, specifically the occurrence of color blindness, maculopathy, and scotoma. </paragraph>
                        <paragraph>However, it is unclear if these eye disorders were dose related. Although the number of reports was very small, certain elderly patients may be predisposed to eye disorders when taking Deferoxamine Mesylate for Injection. Postmarketing reports also suggest that there may be an increased risk of deafness and hearing loss in the geriatric population <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s30">6</linkHtml>)]</content>. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s46">
                     <id root="3361cdcc-0b92-4e43-8c31-2d42874557a9"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is contraindicated in patients with severe renal disease <content styleCode="italics">[see Contraindications (<linkHtml href="#s16">4</linkHtml>)]</content>. </paragraph>
                        <paragraph>For patients with renal impairment, dose selection should usually start at the low end of the dosing range. </paragraph>
                        <paragraph>Deferoxamine can cause increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular disorders <content styleCode="italics">[(see Warnings and Precautions (<linkHtml href="#s20">5.3</linkHtml>)]</content>. Monitor patients for changes in renal function. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s47">
                     <id root="368fe1d4-a2e1-4f50-b616-8fdc4532e3d6"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>For patients with hepatic impairment, dose selection should usually start at the low end of the dosing range. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s48">
               <id root="49b2e5e3-e2cd-409c-b79c-ef8981195c55"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="s49">
                     <id root="b1d91c0a-f10f-4c02-9164-d146e8df735e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Acute Toxicity</content>
                        </paragraph>
                        <paragraph>Intravenous LD<sub>50</sub>s (mg/kg): mice, 287; rats, 329. </paragraph>
                        <paragraph>Inadvertent administration of an overdose or inadvertent intravenous bolus administration/rapid intravenous infusion may be associated with hypotension, tachycardia and gastrointestinal disturbances; acute but transient loss of vision, aphasia, agitation, headache, nausea, pallor, CNS depression, including coma, bradycardia and acute renal failure have been reported. </paragraph>
                        <paragraph>Acute respiratory distress syndrome has been reported following treatment with excessively high intravenous doses of Deferoxamine Mesylate for Injection in patients with acute iron intoxication and in patients with thalassemia. </paragraph>
                        <paragraph>There is no specific antidote for Deferoxamine Mesylate for Injection overdose. In case of overdose, discontinue Deferoxamine Mesylate for Injection and provide symptomatic supportive care. </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection is readily dialyzable. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s50">
               <id root="acbcd92d-48b1-4ae5-b921-5f14269c6b1f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Deferoxamine Mesylate for Injection, USP is an iron-chelating agent, available in vials for injection via intramuscular, subcutaneous, and intravenous administration. Deferoxamine Mesylate for Injection, USP is supplied as vials containing 500 mg and 2 g of deferoxamine mesylate USP (corresponding to 426.82 mg and 1.707 g of deferoxamine as free base) in sterile, lyophilized form. Deferoxamine mesylate is <content styleCode="italics">N</content>- [5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(<content styleCode="italics">N-</content> hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid monomethanesul-fonate (salt), and its structural formula is: </paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Deferoxamine mesylate is a white to almost white powder. It is freely soluble in water and slightly soluble in methanol. Its molecular weight is 656.79 g/mol. </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="def0b-0001-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s51">
               <id root="19c56c46-57a1-4edd-91c1-903ef6f02443"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="s52">
                     <id root="3c7f35a2-5c9b-4b95-803d-1280fe91a92f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. It readily chelates iron from ferritin and hemosiderin but not readily from transferrin; it does not combine with the iron from cytochromes and hemoglobin. </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection does not cause any demonstrable increase in the excretion of electrolytes or trace metals. Theoretically, 100 parts by weight of Deferoxamine Mesylate for Injection is capable of binding approximately 8.5 parts by weight of ferric iron. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s53">
                     <id root="8b39c2ad-7357-4e2b-93fe-35e7b64eb66d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Deferoxamine Mesylate for Injection is metabolized principally by plasma enzymes, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s54">
               <id root="3f9861a2-bb5c-4740-8842-f69827af0684"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="s55">
                     <id root="c9754058-0551-4c01-90db-ca94ae5dd741"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in animals have not been performed with Deferoxamine Mesylate for Injection. Cytotoxicity may occur, since Deferoxamine Mesylate for Injection has been shown to inhibit DNA synthesis <content styleCode="italics">in vitro</content>. </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection was not mutagenic when tested in an in vitro bacterial reverse mutation (Ames) and was not genotoxic in an in vivo micronucleus assay in rats. </paragraph>
                        <paragraph>Animal studies to assess fertility effects have not been conducted. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="e639f5f3-baad-4da7-ba4b-128b13c8f825"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="s57">
                     <id root="a005b950-26ce-4a45-9590-0b71d7993869"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>Deferoxamine Mesylate for Injection, USP is supplied in single-dose vials containing 500 mg and 2 g of deferoxamine mesylate (corresponding to 426.82 mg and 1.707 g of deferoxamine as free base) as a sterile, white to off-white lyophilized powder. </paragraph>
                        <table width="100%">
                           <col width="13%"/>
                           <col width="20%"/>
                           <col width="22%"/>
                           <col width="46%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Product No.</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">NDC No.</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Strength</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Vial size</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>509710 </paragraph>
                                 </td>
                                 <td styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>63323-597-10 </paragraph>
                                 </td>
                                 <td styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>500 mg per vial </paragraph>
                                 </td>
                                 <td styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>10 mL vial packaged individually. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>509930 </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>63323-599-30 </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>2 grams per vial </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>30 mL vial packaged individually. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="4a373971-2198-4c76-97d3-9e0aaea8c980"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">STORE AT: 20</content>ºC to <content styleCode="bold">25</content>°C (<content styleCode="bold">68</content>ºF to <content styleCode="bold">77</content>°F) [see USP Controlled Room Temperature]. </paragraph>
                        <paragraph>The container closure is not made with natural rubber latex. </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s59">
               <id root="46ec5459-2882-492e-a8fb-fa95fdadfd1d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Caution patients about the potential allergic reactions associated with rapid intravenous administration of Deferoxamine Mesylate for Injection and the need for monitoring allergic reactions during treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients about the potential auditory and ocular toxicities due to prolonged use of Deferoxamine Mesylate for Injection, conduct auditory testing and ophthalmic testing at regular intervals. Advise patients to contact their healthcare provider if they develop visual or auditory changes during treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients about the potential for kidney toxicity when taking Deferoxamine Mesylate for Injection and the need for kidney function test to monitor for increase in serum creatinine <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.3</linkHtml>)]</content>. </paragraph>
                  <paragraph>Inform patients that if they have difficulty in breathing during treatment, they should inform the health care provider as this is a symptom of acute respiratory distress syndrome which can occur with excessively high intravenous doses of Deferoxamine Mesylate for Injection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.4</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution pediatric patients and their caregivers that child treated with Deferoxamine Mesylate for Injection could have slower than normal growth and the need to monitor for body weight and height every 3 months <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.5</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients about the increased risk of bacterial infections (<content styleCode="italics">Yersinia enterocolitica and Yersinia pseudotuberculosis</content>) with Deferoxamine Mesylate for Injection treatment and the need for treatment discontinuation until the infection is resolved <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.6</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients about the potential risk of fungal infections (M<content styleCode="italics">ucormycosis</content>) when receiving Deferoxamine Mesylate for Injection treatment and the need for treatment discontinuation, mycological tests and required treatment for treating the infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.6</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients about the potential impairment of cardiac function when taking Deferoxamine Mesylate for Injection concomitantly with high doses of Vitamin C (more than 500 mg daily in adults). Inform adult patients not to exceed a daily Vitamin C dose of 200 mg given in divided doses. Inform pediatric patients under 10 years of age and older pediatric patients or their care takers not to exceed a daily Vitamin C of 50 mg and 100 mg, respectively. <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s14">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s26">5.7</linkHtml>)]</content>. </paragraph>
                  <paragraph>Inform patients with cardiac failure not to take Vitamin C supplements when on treatment with Deferoxamine Mesylate for Injection <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s14">2.4</linkHtml>) and Warnings and Precautions (<linkHtml href="#s26">5.7</linkHtml>)]</content>. </paragraph>
                  <paragraph>Caution patients with aluminum-related encephalopathy and receiving dialysis about potential neurological dysfunction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s27">5.8</linkHtml>)]</content>. </paragraph>
                  <paragraph>Cautions patients that treatment with Deferoxamine Mesylate for Injection in the presence of aluminum overload may result in decreased serum calcium and aggravation of hyperparathyroidism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s27">5.8</linkHtml>)]</content>. </paragraph>
                  <paragraph>Inform patients that they should refrain from driving or operating potentially hazardous machines if they experience dizziness or other nervous system disturbances, or impairment of vision or hearing <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s28">5.9</linkHtml>)]</content>. </paragraph>
                  <paragraph>Advise patients to inform the healthcare provider if they have received prochlorperazine prior to Deferoxamine Mesylate for Injection treatment as this may lead to temporary impairment of consciousness <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s33">7.1</linkHtml>)]</content>. </paragraph>
                  <paragraph>Inform patients that if they are going for any imaging tests while receiving Gallium-67 and Deferoxamine Mesylate for Injection concomitantly it can result in reports with distorted images <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s34">7.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>Inform patients that their urine may occasionally show a reddish discoloration. </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="s60">
                     <id root="32dfcb67-60ff-43f7-a010-0cf339128a5a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-fetal Toxicity:</content>
                        </paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s29">5.10</linkHtml>), Use in Specific Populations (<linkHtml href="#s36">8.1</linkHtml>, <linkHtml href="#s41">8.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraceptive during treatment with Deferoxamine Mesylate for Injection and for one month after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s41">8.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="s61">
                     <id root="dfbad23c-c462-4d04-ae14-7ac2b5736881"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise patients to avoid breastfeeding while taking Deferoxamine Mesylate for Injection and for one week after the final dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s40">8.2</linkHtml>)]</content>. </paragraph>
                        <renderMultiMedia ID="f02" referencedObject="mm02"/>
                        <paragraph>Lake Zurich, IL 60047 </paragraph>
                        <paragraph>www.fresenius-kabi.com/us </paragraph>
                        <paragraph>451101F </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                     <component>
                        <observationMedia ID="mm02">
                           <text>Fresenius Kabi Logo </text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="def0b-0001-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s62">
               <id root="5e910047-0c3d-446a-8d9d-4d5448de5acb"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 500 mg per vial Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-597-10        509710</paragraph>
                  <paragraph>
                     <content styleCode="bold">Deferoxamine Mesylate</content> for Injection, USP </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg per vial</content>
                  </paragraph>
                  <paragraph>For subcutaneous, intramuscular or intravenous use. </paragraph>
                  <paragraph>Rx only </paragraph>
                  <renderMultiMedia ID="id1222" referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 500 mg per vial Vial Label </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="def0b-0001-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s63">
               <id root="915426d8-a08f-42f4-9d00-ef7c6bd53726"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 500 mg per vial Carton Panel</content>
                  </paragraph>
                  <paragraph>NDC 63323-597-10        509710</paragraph>
                  <paragraph>
                     <content styleCode="bold">Deferoxamine Mesylate </content>for Injection, USP </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg per vial</content>
                  </paragraph>
                  <paragraph>For subcutaneous, intramuscular or intravenous use. </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1243" referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 500 mg per vial Carton Panel </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="def0b-0001-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s64">
               <id root="441f5ae7-605b-4c23-9f4e-6505a42663ad"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 2 grams per vial Vial Label</content>
                  </paragraph>
                  <paragraph>NDC 63323-599-30        509930</paragraph>
                  <paragraph>
                     <content styleCode="bold">Deferoxamine Mesylate </content>for Injection, USP </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 grams per vial</content>
                  </paragraph>
                  <paragraph>For subcutaneous, intramuscular or intravenous use. </paragraph>
                  <paragraph>Single-Dose Vial<br/>Rx only </paragraph>
                  <renderMultiMedia ID="id1265" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 2 grams per vial Vial Label </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="def0b-0001-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s65">
               <id root="dedb010c-a62e-4326-97c2-f2779f41bcf0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 2 grams per vial Carton Panel</content>
                  </paragraph>
                  <paragraph>NDC 63323-599-30        509930</paragraph>
                  <paragraph>
                     <content styleCode="bold">Deferoxamine Mesylate</content> for Injection, USP </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 grams per vial</content>
                  </paragraph>
                  <paragraph>For subcutaneous, intramuscular or intravenous use. </paragraph>
                  <paragraph>Rx only </paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <renderMultiMedia ID="id1287" referencedObject="MM6"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PACKAGE LABEL - PRINCIPAL DISPLAY - Deferoxamine Mesylate 2 grams per vial Carton Panel </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="def0b-0001-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>